Taken together, these findings identify FGF21 as a biomarker that provides insight into the clinical heterogeneity and pathophysiology of ALS while at the same time identifying it as a potential target for future therapeutic development. The gene discussed is FGF21; the disease is amyotrophic lateral sclerosis.